Equity
DEFOPHARMA has made a profit in every financial year since 2020.
DEFOPHARMA has made a profit in every financial year since 2020.
Latest accounts filed late: after the legal deadline.
Subsidiary with negative equity. PHARMACIE ARNAUD NICOLAS · loss of €36,596 in 2025.
The dashed line is the sector median: 0.1% across 48,570 companies (NACE 70, micro).
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 43% of them on solvency, 24% on liquidity, 28% on profitability and 71% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Liquidity is tight, with a current ratio of 1.41 (1.16 in 2024), below the usual 1.5. Short-term debt is 20.1% and cash 0.3% of total assets. 53.2% of the assets are financed with debt and provisions.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The company filed its last 5 accounts on average 41 days after the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
| Company | ||||
|---|---|---|---|---|
| DEFOPHARMA Lessines | €181,427 | €23,185 | 46.8% | - |
| MDR ADVISORY Namur | €172,708 | €23,146 | 23.3% | - |
| LOF Consulting Oud-Heverlee | €199,338 | €23,381 | 23.5% | - |
| Guide2Grow Kortenberg | €172,797 | €23,705 | 83.4% | - |
| Kerhall Consulting Ixelles | €180,912 | €24,504 | 88.5% | - |
| Triksa Destelbergen | €188,908 | €22,292 | 9.1% | - |
| JAHSOLUTIONS Ixelles | €171,144 | €25,344 | 12.0% | - |
These companies have the same main activity as DEFOPHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €171,000 and €199,000, founded between 2019 and 2020.
DEFOPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €11,953 in 2020 to €23,185 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.